A secondary analysis of TRAILBLAZER-ALZ 2 strengthens the case that reducing amyloid plaques underlies the clinical benefits ...

The nanoparticles act as tiny engineers of cellular behavior, the researchers explain, orchestrating repair at the molecular ...

Johns Hopkins scientists uncovered microscopic “nanotube” channels that neurons use to transfer toxic molecules. While this ...

In a study published in Neuron, a research team at the Department of Neurology at Massachusetts General Hospital, aimed to ...

Scientists are unraveling the molecular mechanisms of Alzheimer’s to develop earlier diagnoses and breakthrough therapies ...

Openwater has developed a low-intensity focused ultrasound device that might one day noninvasively disrupt microclots in long ...

The US Food and Drug Administration (FDA) has granted clearance for Roche's Elecsys pTau181 test, a blood-based biomarker ...

Discover how donanemab’s impact on posttreatment amyloid levels may transform Alzheimer’s treatment. Keep reading to learn ...

A new study has identified a mutation in the TREM2 gene that disrupts the brain’s ability to clear toxic amyloid plaques, increasing Alzheimer’s disease risk.

A clinical trial from Wake Forest University School of Medicine shows that two widely available medications, the diabetes ...

Recent Food and Drug Administration approval of the first two blood tests used in detecting Alzheimer’s disease brings hope ...

A new study shows that a single injection of specially designed nanoparticles can dramatically reduce levels of a toxic ...